Dovato

RSS

dolutegravir / lamivudine

Authorised
This medicine is authorised for use in the European Union.

Overview

Dovato is a medicine for treating infection with human immunodeficiency virus type 1 (HIV-1) in adults and adolescents over 12 years old who weigh at least 40 kg.

This medicine contains the active substances dolutegravir and lamivudine and is used to treat infections that are not resistant to medicines of the same class as dolutegravir or to lamivudine.

This EPAR was last updated on 04/09/2019

Authorisation details

Product details
Name
Dovato
Agency product number
EMEA/H/C/004909
Active substance
  • dolutegravir sodium
  • lamivudine
International non-proprietary name (INN) or common name
  • dolutegravir
  • lamivudine
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Date of issue of marketing authorisation valid throughout the European Union
01/07/2019

Product information

Dovato - EMEA/H/C/004909 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Dovato is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.

Assessment history

How useful was this page?

Add your rating